Immuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong
HONG KONG SAR - Media OutReach Newswire - 26 January 2026 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today the initiation of a Phase I clinical study of ICVAX, a therapeutic DNA vaccine for HIV, in collaboration with the Faculty of Medicine of The Chinese University of Hong Kong ("CUMedicine"), the AIDS Institute of The University of Hong Kong ("HKU AIDS Institute"), and Greater Bay Area International Clinical Trials Center ("BAY TRIAL").